Legal & General Group Plc Buys Shares of 68,988 Repligen Corporation $RGEN

Legal & General Group Plc purchased a new stake in Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 68,988 shares of the biotechnology company’s stock, valued at approximately $9,413,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of Nova Scotia purchased a new position in Repligen during the 2nd quarter valued at about $3,547,000. Avidity Partners Management LP raised its position in Repligen by 54.7% during the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after acquiring an additional 27,500 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in shares of Repligen in the second quarter valued at about $655,000. Swedbank AB purchased a new stake in shares of Repligen in the fourth quarter valued at about $4,146,000. Finally, B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Repligen in the second quarter valued at approximately $3,597,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on RGEN. Wolfe Research started coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective for the company. Citigroup upgraded Repligen to a “buy” rating in a report on Tuesday, July 7th. Royal Bank Of Canada started coverage on Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Barclays boosted their price target on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, HSBC reduced their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $166.43.

Repligen Stock Performance

NASDAQ:RGEN opened at $170.02 on Wednesday. The firm has a 50 day simple moving average of $153.95 and a 200-day simple moving average of $133.50. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The firm has a market cap of $9.60 billion, a PE ratio of 232.90, a P/E/G ratio of 3.30 and a beta of 1.04. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. Repligen’s revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities analysts expect that Repligen Corporation will post 2.06 EPS for the current year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.